期刊文献+

解毒消瘰方治疗非霍奇金淋巴瘤的疗效及对Th17/Treg细胞水平的影响 被引量:2

Observation of clinical effect of Jiedu xiaoluo recipe on non-hodgkin lymphoma
下载PDF
导出
摘要 目的观察解毒消瘰方治疗非霍奇金淋巴瘤的临床疗效及其对Th17/Treg和相关因子水平的影响。方法按照治疗方案不同将60例非霍奇金淋巴瘤病患者分为对照组和治疗组,各30例。对照组应用常规治疗,治疗组在对照组基础上加用解毒消瘰方,连用4个疗程。比较两组总缓解率、Th17/Treg细胞及相关细胞因子等情况。结果两组总缓解率差异无统计学意义,治疗组Th17细胞百分率及IL17水平较对照组高(均P <0.05);Treg细胞百分率及TGF-1水平较对照组低(均P <0.05)。结论解毒消瘰方治疗非霍奇淋巴瘤可改善临床症状,降低Treg细胞百分率及TGF-1水平,升高Th17细胞百分率及IL17水平。监测外周血Th17/Treg及其相关因子水平的变化对非霍奇金淋巴瘤预后判定可能有重要的临床意义。 Objective To observe the clinical effect of Jieduxiaouo recipe on non-hodgkin lymphoma. Methods Sixty patients with non-Hodgkin lymphoma were randomly divided into control group and treatment group with 30 cases in each group. The control group was treated with routine treatment, while the treatment group was treated with Jiedu xiaoluo recipe on the basis of the control group. After four courses of treatment, the total remission rate, Th17/treg cells and related cyto- kines of both groups were observed. Results Overall remission rate of treatment and control group was 86.67% and 83.33%, respectively. The percentage of Th17 cells and the level ofIL 6 in the treatment group were significantly higher than those in the control group ( allP 〈 0.05). Treg cell percentage and TGF-β1 level were significantly lower than those of the control group ( all P 〈 0.05). Conclusion Jiedu xiaoluo recipe can improve clinical symptoms, reduce treg cell percentage and TGF-β 1 level, increase Thl 7 cell percentage and IL 17 level in treating non-hodgkin lymphoma.
作者 许晓娜 张宇 宋岩松 李航超 周郁鸿 XU Xiaona;ZHANG Yu;SONG Yansong;LI Hangchao;ZHOU Yuhong(The First Affiliated Hospital to Zhejiang Chinese Medical University Hangzhou 310053,Zhejiang,China)
出处 《现代实用医学》 2018年第9期1135-1137,共3页 Modern Practical Medicine
基金 国家中医临床研究基地业务建设第二批科研专项(2015H0105) 浙江省医药卫生科技计划项目(2017KY116)
关键词 非霍奇金淋巴瘤 解毒消瘰方中医药 Non-hodgkin lymphoma Jieduxiaouo recipe Traditional Chinese Medicine
  • 相关文献

参考文献4

二级参考文献37

  • 1刘莉,姚军霞,丁乾,黄士昂.非霍奇金淋巴瘤患者外周血CD4^+CD25^(high)调节性T细胞研究[J].中国实验血液学杂志,2006,14(1):119-122. 被引量:30
  • 2Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 2009, 30 (7) : 1073-1081.
  • 3Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell, 2011, 144(5) :646-674.
  • 4Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 2005, 6(11) :1133-1141.
  • 5Dong C. TH17 ceils in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol, 2008, 8 (5) :337-348.
  • 6Su X, Ye J, Hsueh EC, et al. Tumor microenvironments direct the recruitment and expansion of human Thl7 cells. J Immunol, 2010, 184(3 ) : 1630-1641.
  • 7Zhu X, Mulcahy LA, Mohammed RA, et al. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res, 2008, 10(6) :R95.
  • 8Wu S, Rhee KJ, Albesiano E, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med, 2009, 15(9) :1016-1022.
  • 9Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinieal relevance of Thl7 cells in the human tumor environments. Blood, 2009, 114 (6) : 1141-1149.
  • 10Koyama K, Kagamu H, Miura S, et al. Reciprocal CD4^+ T-cell bal- ance of effector CD62Llow CD4^+ and CD621highCD25^+ CD4^+ regulatory T ceils in small cell lung cancer reflects disease stage. Clin Cancer Res, 2008, 14(21) : 6770-6779.

共引文献15

同被引文献20

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部